Traditionally, conventional induction chemotherapy has been the primary frontline treatment for acute myeloid leukemia (AML); however, older adults are often poor chemotherapy candidates. Recently, several nonconventional frontline AML regimens, including hypomethylating agents, the BCL-2 inhibitor venetoclax, and targeted therapies, have emerged, and they may offer new options for older adults. This study was aimed at describing treatment patterns and outcomes of older adult AML in a modern population-based cohort.

中文翻译：

---

老年人急性髓性白血病的一线治疗模式和结果：现代基于人群的分析

传统上，常规诱导化疗一直是急性髓性白血病（AML）的主要一线治疗方法。然而，老年人通常不适合化疗。最近，出现了几种非常规的一线 AML 治疗方案，包括低甲基化药物、BCL-2 抑制剂 venetoclax 和靶向治疗，它们可能为老年人提供新的选择。本研究旨在描述现代人群队列中老年人 AML 的治疗模式和结果。